The Spanish Prime Minister, Pedro Sánchez, makes an institutional visit to ROVI’s facility in San Sebastián de los Reyes (Madrid)

During the visit, he was accompanied by the Minister of Science and Innovation, Pedro Duque, and the Director of the Spanish Medicines and Health Products Agency (AEMPS), María Jesús Lamas.

ROVI’s CEO, Juan López-Belmonte; the Deputy Chairman and CFO, Javier López-Belmonte, the Deputy Chairman and Corporate Development Manager, Iván López-Belmonte, and the Industrial Production Manager, Miguel Ángel Ortega, showed them round the facility.

ROVI’s plant in San Sebastián de los Reyes (Madrid) is specialised in the production of injectables and will take part in the fill-finish process of Moderna’s candidate COVID-19 vaccine.


This morning, the facility of Laboratorios Farmacéuticos ROVI, S.A. (ROVI) in San Sebastián de los Reyes (Madrid) received an institutional visit from the Spanish Prime Minister, Pedro Sánchez, the Minister of Science and Innovation, Pedro Duque, and the Director of the Spanish Medicines and Health Products Agency (AEMPS), María Jesús Lamas

During their tour of the plant, they were accompanied by ROVI’s CEO, Juan López-Belmonte; the Deputy Chairman and CFO, Javier López-Belmonte, the Deputy Chairman and Corporate Development Manager, Iván López-Belmonte, and the Industrial Production Manager, Miguel Ángel Ortega.

ROVI’s plant in San Sebastián de los Reyes (Madrid) is specialised in the production of injectables and will take part in the large-scale manufacturing process of the fill-finish process of Moderna’s candidate mRNA COVID-19 vaccine (mRNA-1273).

From its facility, ROVI will provide support to the production of hundreds of millions of doses of the candidate vaccine to supply markets outside the U.S.A. as of the beginning of 2021. To this end, the company has had to acquire a new production line and equipment for compounding, filling, automatic visual inspection and labelling. Furthermore, it has also hired the additional staffing required for the manufacturing and production operations.

During his speech to ROVI’s workers and management team, the Prime Minister, Pedro Sánchez, highlighted the company’s track record over recent decades and thanked it for its contribution to overcoming the COVID-19 pandemic as a large-scale manufacturer of the Moderna vaccine.

“I would like the congratulate Laboratorios ROVI because you are a clear example a Spanish family company in the vanguard of innovation, research and development. I congratulate you on your work and because you are a company formed by young people with a strong commitment to your country. It is a matter of great pride for a Spanish company to manufacture in Spain one of the first vaccines against the COVID-19 pandemic. You are a source of inspiration and peace of mind for all the country’s citizens”, said the Prime Minister, Pedro Sánchez, in his speech after visiting the San Sebastián de los Reyes facilities.

ROVI’s CEO, Juan López-Belmonte, thanked the Spanish government and the Spanish Medicines Agency for their visit to the facilities in San Sebastián de los Reyes (Madrid) and their support over the last few months.

“At ROVI, we are very excited to be able to collaborate with Moderna and form part of the solution to the global pandemic. The task of supplying their vaccine on a large scale (the whole world except the United States) is good news for the company, but also for the whole Spanish pharmaceutical industry and Spain as a country. Our proven experience and capabilities as a contract manufacturer of injectables has made it possible to reach this agreement”, remarked  Juan López-Belmonte.

No votes yet
 
Related
ROVI will donate a million surgical masks to the Ministry of Health
Since the beginning of the health crisis caused by the expansion of COVID-19, ROVI has been taking measures to ensure the continuity of its...
1 min
26/03/2020
ROVI reports operating revenue growth of 26% and EBITDA growth of 106%
Operating revenue increased by 26% to 381.3 million euros in 2019, mainly driven by the strength of the specialty pharmaceutical...
6 min
26/02/2020